
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934

For the month of May 2025

Commission File Number: 001-14014

CREDICORP LTD.

(Translation of registrant's name into English)

Of our subsidiary
Banco de Credito del Peru:
Calle Centenario 156
La Molina 15026
Lima, Peru

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____



May 19, 2025

Securities and Exchange Commission - SEC
Re.: MATERIAL EVENT

Dear Sirs:

We hereby notify that, pursuant to the request made by the Peruvian Superintendency of Securities Market through Official Letter N.º 2302-2025-SMV/11.1 and Official Letter N.º 2816-2025-SMV/11.1, we complied with the disclosure of the aforementioned Official Letters as a Material Event to the Peruvian Market. The attached Official Letters were translated into English from the original in Spanish.

The information in this Form 6-K (including any exhibits hereto) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the ‘Exchange Act’) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Sincerely,

/s/ Guillermo Morales
Authorized Representative
Credicorp Ltd.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 19, 2025

CREDICORP LTD.
(Registrant)

By: /s/ Guillermo Morales
Guillermo Morales
Authorized Representative

San Isidro, April 24, 2025

OFFICIAL LETTER No. 2302-2025-SMV/11.1

Mr.

Gianfranco Piero Dario Ferrari de las Casas
Chief Executive Officer
Credicorp Ltd.
Clarendon House 2 Church Street Hm11
Bermuda.-

Ref.: File No. 2025017716

I am writing to you in relation to the mandatory legal provisions established in Articles 10 and 30 of the Consolidated Text of the Securities Market Law, Legislative Decree No. 861, approved by Supreme Decree No. 020-2023-EF (hereinafter, TUO LMV), as well as the provisions of Article 3 of the Regulation of Material Events and Reserved Information, approved by SMV Resolution No. 005-2014-SMV/01 and its amending regulations (hereinafter, Regulation HI), by virtue of which Credicorp Ltd. (hereinafter, Credicorp), as an issuer with securities registered in the Public Registry of the Securities Market – RPMV, has the obligation to disclose all information about itself and/or its economic group that qualifies as a material event, ensuring that its disclosure meets the requirements of truthfulness, sufficiency, and timeliness, and considering that such disclosure is done in the manner and within the timeframe established by the Regulation HI.

It is also necessary to point out that, according to the information provided by your representative in its Economic Group Report¹, La Esperanza del Perú S.A. (hereinafter, Clínica SANNA San Borja) and Clínica Sánchez Ferrer S.A. (hereinafter, Clínica SANNA Trujillo) —which are part of the SANNA Clinic Network— belong to the Credicorp Economic Group, with Credicorp being the ultimate controller of the indicated companies.

In this regard, it should be noted that, since the end of March 2025 and to date, news has been disseminated about the serious events that occurred at Clínica SANNA San Borja and Clínica SANNA Trujillo, related to the administration of defective saline solution to various patients, which has resulted in fatalities. Among that news we have the following:

- (i) A statement dated March 26, 2025², in which SANNA reported, among other things, that on Monday, March 24, the pharmaceutical laboratory Medifarma made public that it had marketed a defective batch of saline solution and proceeded to withdraw it from its distribution points. They also reported that two patients at Clínica SANNA Trujillo, who were administered the saline solution from the mentioned batch, had died. Additionally, they indicated that two patients at Clínica SANNA San Borja were in critical health condition for the same reason and that they had learned that a person who had initially been treated at that institution with the same saline solution, and later transferred to another health center, had also died.
- (ii) The RPP website on March 26, 2025³, titled "Clínica Sanna confirms that two more people died after receiving saline solution observed by the Ministry of Health (Minsa)".
- (iii) Semana Economica on March 27, 2025⁴, titled "Clínica Sanna confirmed two deaths and serious patients due to defective Medifarma saline solution".

¹ Economic Group Report as of April 14, 2025.

Link: <https://www.smv.gob.pe/ConsultasP8/documento.aspx?vidDoc=%7b80623696-0000-C85C-9B4F-4575FA66B57E%7d>

² Link: <https://web.facebook.com/photo/?fbid=1062529522576797&set=comunicado>

³ Link: <https://rpp.pe/peru/actualidad/clinica-sanna-confirma-que-dos-personas-mas-murieron-trasrecibir-suero-fisiologico-observado-por-el-minsa-noticia-1624470>

⁴ Link: <https://www.semanaeconomica.com/sectores-empresas/salud/clinica-sanna-confirmando-dos-fallecidos-y-pacientes-graves-por-suero-defectuoso-de-medifarma>

- (iv) Press Release No. 007-2025 dated March 29, 2025⁵, in which the Ministry of Health – MINSA, through its Attorney General's Office, reported having "criminally denounced Clínica SANNA and those responsible for failing to report in a timely manner (within the required 24 hours) the first serious adverse reaction that resulted in death, notifying it only a month later".
- (v) The Infobae website on April 1, 2025⁶, titled "Ministry of Health (Minsa): Sanna alerted about the death of a patient due to defective Medifarma saline solution one month after the death".
- (vi) Diario Gestion on April 1, 2025⁷, titled "Defective saline solution: SANNA gives its version of why its Trujillo clinic could not identify it".
- (vii) The Ojo Publico website on April 13, 2025⁸, titled "Medifarma case: the defective saline solution that exposed cracks in the health system".
- (viii) The RPP website on April 17, 2025⁹, titled "Nurse who was in critical condition after being administered saline solution at Clínica Sanna dies".
- (ix) El Comercio website on April 19, 2025¹⁰, titled "Architect dies after being in brain death for a month: the number of victims of Medifarma's defective saline solution rises to 7".

Consequently, without prejudice to the determination of responsibilities that may arise, within the framework of the oversight actions of the General Office of Conduct Supervision – IGSC, based on the provisions of Article 27, numeral 27.3, of the Regulation HI, and considering the aforementioned events, your representative is required to do the following:

1. Explain the reasons why your representative has not yet disclosed as a relevant event all the information related to the events that occurred at Clínica SANNA San Borja and Clínica SANNA Trujillo.
2. Disclose all the information related to the administration of defective saline solution to various patients in the SANNA Clinic Network.
3. Confirm and/or clarify all the information about the judicial process initiated by the Ministry of Health (MINSA) against the SANNA Clinic Network.
4. Inform whether there are any administrative processes initiated by Peruvian State authorities against any of the clinics in the SANNA Clinic Network, belonging to your economic group, or against their respective officials.
5. Provide detailed information on all the agreements adopted by the governing bodies of your representative or the companies in your economic group in relation to the serious events indicated. If no agreement has been adopted, inform this situation, indicating the reasons.
6. Provide all information related to the economic/financial impact generated by the aforementioned events and their consequences on your representative and/or the companies in your economic group, as well as the measurement of such impact to date.
7. Provide all information related to the measurement of the reputational impact on your representative and the companies in your economic group.
8. Provide detailed information on any other relevant additional information on the matters of this official letter.

⁵ Link: <https://www.gob.pe/institucion/minsa/noticias/1136391-comunicado-de-prensa-n-007-2025>

⁶ Link: <https://www.infobae.com/peru/2025/04/01/sanna-alerto-sobre-muerte-de-paciente-por-suero-defectuoso-de-medifarma-un-mes-despues-del-deceso-segun-minsa/>

⁷ Link: <https://gestion.pe/peru/suero-defectuoso-sanna-da-su-version-de-el-porque-su-clinica-de-trujillo-no-pudo-identificarlo-noticia/>

⁸ Link: <https://ojo-publico.com/derechos-humanos/salud/medifarma-el-caso-que-expuso-las-grietas-del-sistema-sanitario>

⁹ Link: <https://rpp.pe/lima/actualidad/fallece-enfermera-que-se-encontraba-en-estado-critico-tras-aplicarle-suero-fisiologico-en-clinica-sanna-noticia-1629204>

¹⁰ Link: <https://elcomercio.pe/lima/sucesos/medifarma-fallece-arquitecta-de-26-anos-tras-permanecer-un-mes-con-muerte-cerebral-ya-son-7-las-victimas-del-suero-defectuoso-sanna-san-borja-ultimas-noticia/>

This requirement must be met within a maximum period of two (02) business days from the notification of this official letter, through the corresponding route of the "Material Events " of the MVNet System; notwithstanding this, you must proceed to publish this official letter immediately through the Material Events route.

Finally, your representative is required, in compliance with the cited regulations, to fulfill its obligation to keep the market informed of any act, agreement, fact, ongoing negotiation, decision, or set of circumstances with significant influence, taking the necessary measures to ensure full compliance with the obligations arising from the securities market regulations, as well as to address the requirements made by the Superintendence of Securities Market.

Without further ado, I remain at your disposal.

Sincerely,

Alix Godos
Head of Conduct Supervision
General Office of Conduct Supervision

JHT/EVC
C.C. Lima Stock Exchange S.A.

San Isidro, May 15, 2025

OFFICIAL LETTER No. 2816-2025-SMV/11.1

Mr.

Gianfranco Piero Dario Ferrari de las Casas
Chief Executive Officer
Credicorp Ltd.
Clarendon House 2 Church Street Hm11
Bermuda.-

Ref.: File No. 2025017716
Official Letter No. 2302-2025-SMV/11.1
Letter dated April 24, 2025

Dear Sir,

I am writing to you regarding the following:

- (i) Official Letter No. 2302-2025-SMV/11.1 (hereinafter, “Official Letter No. 2302”), through which the General Office of Conduct Supervision (IGSC) made several requests for information to Credicorp Ltd. (hereinafter, “Credicorp”) regarding the serious incidents that occurred within the SANNA Clinic Network, related to the administration of defective saline solution to various patients, which resulted in fatalities. Additionally, Credicorp was requested to immediately disclose the Official Letter No. 2302 as a material event, notwithstanding the deadline granted for responding to the information requests.
- (ii) Letter dated April 24, 2025, in which Credicorp responded to Official Letter No. 2302.

April 24, 2025

SUPERINTENDENCY OF THE SECURITIES MARKET – SMV

Attn.: Mr. Alix Godos – Head of Conduct Supervision
General Office of Conduct Supervision

Ref.: Official Letter No. 2302-2025-SMV/11.1

Dear Sirs,

In response to the referenced Official Letter, we consider that the entity best positioned to respond and inform the market regarding the matters indicated therein is Pacífico Compañía de Seguros y Reaseguros S.A. (hereinafter, “Pacífico”), in its capacity as direct shareholder of Pacífico S.A. Entidad Prestadora de Salud, owner of La Esperanza del Perú S.A. (Clínica SANNA San Borja) and Clínica Sánchez Ferrer S.A. (Clínica SANNA Trujillo). Accordingly, we respectfully request that this Superintendency redirect the aforementioned request to Pacífico so that it may address the matter. It is worth noting that Pacífico is a company whose shares are registered in the Public Registry of the Securities Market.

Sincerely,

CREDICORP LTD.

(iii) Letter dated April 28, 2025, through which Credicorp stated: “(...) we would like to reiterate our communication dated April 24, 2025, a copy of which is attached, and we remain attentive to your response at your earliest convenience.”

In this regard, it is necessary to reiterate that, according to the Economic Group Report¹ submitted by your company, **Credicorp exercises final control over the economic group known as “Credicorp”**, which includes La Esperanza del Perú S.A. and Clínica Sánchez Ferrer S.A. Therefore, the Official Letter was addressed to Credicorp in **its capacity as the ultimate controller of the SANNA Clinic Network**, which is part of its economic group².

Furthermore, pursuant to Articles 10 and 30 of the Consolidated Text of the Securities Market Law, Legislative Decree No. 861, approved by Supreme Decree No. 020-2023-EF (hereinafter, TUO LMV), as well as the provisions of Article 3 of the Regulation on Material Events and Reserved Information, approved by SMV Resolution No. 005-2014-SMV/01 and its amendments (hereinafter, Regulation HI), **Credicorp**, as an issuer with securities registered in the Public Registry of the Securities Market (RPMV) and as the controller of the “Credicorp” economic group, **has the obligation to disclose all information about itself and/or its economic group that qualifies as a material event**, ensuring that its disclosure meets the requirements of truthfulness, sufficiency, and timeliness, and considering that such disclosure is done in the manner and within the timeframe established by the Regulation HI.

Therefore, without prejudice to the determination of responsibilities that may arise, and within the framework of the SMV’s supervisory actions, and pursuant to Article 27 of the Regulation HI, Credicorp is hereby required to, within a maximum of two (2) business days from notification of this official letter, comply with the requests made in Official Letter No. 2302 through the corresponding route of the "Material Events " of the MVNet System.

Additionally, Credicorp is required to immediately disclose both Official Letter No. 2302 and this official letter through the corresponding route of the "Material Events " of the MVNet System. Failure to do so will result in the SMV proceeding with the disclosure itself, pursuant to Article 27.1 of the Regulation HI.

Finally, we reiterate that your company must comply with its obligation to keep the market informed of any act, agreement, fact, ongoing negotiation, decision, or set of circumstances with significant influence on the market, taking the necessary measures to ensure full compliance with the obligations arising from the securities market regulations, as well as to address the requirements made by the SMV. It is important to note that failure to comply with these requirements constitutes a sanctionable offense under Section 1.1, Item 1, Part B, Annex II of the Sanctions Regulation, approved by SMV Resolution No. 035-2018-SMV/01.

¹ Economic Group Report as of April 14, 2025. Link:

<https://www.smv.gob.pe/ConsultasP8/documento.aspx?vidDoc=%7b80623696-0000-C85C-9B4F-4575FA66B57E%7d>

² The SANNA Clinic Network is composed — among others — of Sistemas de Administración Hospitalaria S.A.C., La Esperanza del Perú S.A. (Clínica San Borja), and Clínica Sánchez Ferrer S.A. (located in Trujillo), all of which are controlled by Pacífico S.A. Entidad Prestadora de Salud. In turn, Pacífico S.A. is jointly owned by Pacífico Compañía de Seguros y Reaseguros S.A. (50%) and Grupo Crédito S.A. (50%), both of which are subsidiaries of Credicorp Ltd.

Sincerely,

Alix Godos
Head of Conduct Supervision
General Office of Conduct Supervision

JH/EV

Cc: Pacífico Compañía de Seguros y Reaseguros S.A.
 Lima Stock Exchange S.A.
